AstraZeneca Annual Report and Form 20-F Information 2011

Following the acquisition of Novexel in 2010,we are collaborating with Forest on theco-development and commercialisation of twolate stage antibiotic development programmes.In 2011, we announced that one of these,ceftazidime/avibactam (CAZ AVI), is enteringPhase III trials to investigate its efficacy in treatingpatients with complicated intra-abdominal andurinary tract infections.> AstraZeneca is one of four companies to havesigned up to partner with TB Alliance and theWorld Health Organization in a six-way alliancethrough which the companies will shareinformation about the tuberculosis (TB)compounds in their pipelines to quickly identifyand collaborate to develop the most promisingTB drug regimen, regardless of sponsor. Formedunder the Critical Path to TB Drug Regimens(CPTR) initiative, the partnership facilitates amore collaborative approach to TB drugdevelopment. It aims dramatically to speed upthe development of shorter, safer and moreeffective multi-drug treatments which areurgently needed to control the globalTB pandemic.We have a long-standingculture of collaborationand 57,200 peopleworldwide dedicatedto working with eachother and with ourstakeholders to improvehealthcare.6 of 9Six of our nine Phase III products are the resultof successful partnerships (67%).> The Scrip Award for the Best PartnershipAlliance was won by our Colorectal CancerCollaboration with molecular diagnosticscompany Agendia and the NetherlandsCancer Institute. The two-year partnershiphas the objective of accelerating thedevelopment of targeted therapies forcolorectal cancer by segmenting it atthe molecular level. A key feature of thepartnership is that personalised diagnosticsmay be developed far earlier in thedevelopment process for new drugsthan has previously been possible.28 Health CollaborationAstraZeneca Annual Report and Form 20-F Information 2011